Oregon Health & Science University
Hospital and Clinics Provider's Orders

PO9031

ADULT AMBULATORY INFUSION ORDER

Darbepoetin Alfa (ARANESP) Initiation

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

Weight: _____kg **Height:** _____cm

Allergies: _____

Diagnosis Code: _____

Treatment Start Date: _____ **Patient to follow up with provider on date:** _____

****This plan will expire after 365 days at which time a new order will need to be placed****
****This order set is for INITIAL DOSE ONLY. For continued maintenance dosing, providers MUST fill out appropriate darbepoetin alfa maintenance order set****

INDICATION: ***(Must check one)***

- ☐ Anemia of Chronic Kidney Disease (CKD)
- ☐ Chemotherapy-induced anemia
- ☐ Symptomatic anemia associated with myelodysplastic syndrome (MDS)

GUIDELINES FOR ORDERING

1. Send **FACE SHEET and H&P or most recent chart note**.
2. OHSU's formulary erythropoiesis stimulating agent (ESA) is darbepoetin alfa (ARANESP). All orders for epoetin alfa (PROCRIT) will be converted to darbepoetin alfa using equivalent therapeutic interchange dosing listed in the table below. Providers who prefer to use epoetin alfa must specify a reason for its use and utilize an alternate ordering form.
3. All patients must be negative when evaluated for blood loss, hemolysis, and bone marrow fibrosis prior to initiation of therapy. Providers must assess and replete iron, folate, and Vitamin B12 prior to any treatment with erythropoiesis stimulating agent.
4. Patients receiving concurrent treatment with Iron Sucrose (VENOFER) and/or Vitamin B12 cannot receive ESA treatment on the same day. Patients may be on prophylactic oral iron supplementation concurrent with ESA treatment as long as supplementation for the prevention of iron deficiency is necessary due to ESA therapy alone.
5. Hemoglobin and hematocrit must be obtained within 1 week of therapy initiation. Hemoglobin must be less than 10 g/dL or hematocrit must be < 30% prior to initiation. Serum ferritin and transferrin saturation (TSAT) must be performed every month during initial (ESA) treatment and at least every 3 months during stable ESA treatment (serum ferritin >100 ng/mL, and TSAT >20%).
6. For patients with anemia of CKD: The medical record must display documentation that anemia is clearly attributed to a CKD diagnosis. The specific CKD stage must be moderate (stage III) to end stage.
7. **For patients with chemotherapy-induced anemia**: The medical record must document the provider's rationale for determining the anemia is "chemotherapy-induced." Anemia must be secondary to myelosuppressive anticancer chemotherapy in solid tumors, multiple myeloma, lymphoma, or lymphocytic leukemia. Treatment should be limited to the 8 weeks following myelosuppressive chemotherapy.
8. **For patients with symptomatic anemia from MDS**: The patient must be symptomatic and his/her life expectancy must be >3 months. The medical record must display documentation that a bone marrow biopsy has been reviewed by a provider and is consistent with the diagnosis of MDS. The marrow blast count must be <5%

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

LABS:

- ☐ Hemoglobin & Hematocrit, Routine, ONCE
- ☐ CMP, Routine, ONCE
- ☐ Ferritin (serum), Routine, ONCE
- ☐ Iron and TIBC (serum), Routine, ONCE
- ☐ Vitamin B-12 (serum), Routine, ONCE
- ☐ Labs already drawn. Date: _____

(Note: These labs are to accompany initiation of treatment and only occur once. Maintenance labs must be ordered on the maintenance order set.)

MEDICATIONS:

- **darbepoetin alfa (ARANESP), subcutaneous, ONCE**
  Initiate first dose within 1 week of obtaining baseline labs.
  Pharmacist will round dose to nearest vial size if within 10% of original dose during verification

  Anemia of Chronic Kidney Disease:
  - ☐ 0.45 mcg/kg = _____ units

  Chemotherapy-induced anemia:
  - ☐ 2.25 mcg/kg = _____ units

  Symptomatic anemia associated with MDS:
  - ☐ 150 mcg
  - ☐ 300 mcg

  Fixed dose regimens: (must check one)

  Dose:
  - ☐ 25 mcg
  - ☐ 40 mcg
  - ☐ 60 mcg
  - ☐ 100 mcg
  - ☐ 150 mcg
  - ☐ 200 mcg
  - ☐ 300 mcg

  Interval:
  - ☐ Once
  - ☐ _____ times per _____ x _____

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

NURSING ORDERS:

1. Patients receiving concurrent treatment with Iron Sucrose (VENOFER) and/or Vitamin B12 cannot receive ESA treatment on the same day.
2. Hemoglobin and hematocrit must be obtained within 1 week of therapy initiation. Hemoglobin must be less than 10 g/dL or hematocrit must be less than 30% prior to initiation. Serum ferritin should be greater than 100 ng/mL and transferrin saturation should be greater than 20%. Hold treatment and call provider if lab parameters are not met or if blood pressure is greater than 180 systolic or 100 diastolic.
3. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes.

OTHER:

Conversion from epoetin alfa (PROCRIT) to darbepoetin alfa (ARANESP): Initial adult dosing

Epoetin alfa dose (units/week)	Darbepoetin alfa dose (mcg/week)
<1500	6.25
1500-2499	6.25
2500-4999	12.5
5000-10,999	25
11,000-17,999	40
18,000-33,999	60
34,000-89,999	100
≥90,000	200

In patients receiving epoetin alfa 2-3 times weekly, darbepoetin should be given once weekly. If epoetin is administered once weekly, darbepoetin should be given once every 2 weeks. Darbepoetin dosing every 2 weeks should be determined by adding the 2 weekly epoetin alfa doses, then convert to appropriate corresponding darbepoetin dose. Doses should be titrated to hemoglobin response thereafter

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

By signing below, I represent the following:
I am responsible for the care of the patient (*who is identified at the top of this form*);
I hold an active, unrestricted license to practice medicine in: ☐ Oregon ☐ _____ (*check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon*);

My physician license Number is # _____ (MUST BE COMPLETED TO BE A VALID PRESCRIPTION); and I am acting within my scope of practice and authorized by law to order Infusion of the medication described above for the patient identified on this form.

Provider signature: _____ **Date/Time:** _____

Printed Name: _____ **Phone:** _____ **Fax:** _____

Please check the appropriate box for the patient's preferred clinic location:

☐ TUALITY HEALTHCARE
An OHSU Partner

Infusion Services
364 SE 8th Ave, Medical Plaza Suite 108B
Hillsboro, OR 97123
Phone number: (503) 681-4124
Fax number: (503) 681-4120

☐ MCMC
MID-COLUMBIA MEDICAL CENTER
A Planetree Patient-Centered Hospital

Celilo Cancer Center
1800 E 19th St
The Dalles, OR 97058
Phone number: (541) 296-7585
Fax number: (541) 296-7610